Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers

Summary

It is probable that a mucosal approach is necessary for a prophylactic HIV vaccine protecting against sexually transmitted infection. Mucosal immune responses have been almost non-existent in trials of HIV vaccine candidates in which the antigen was delivered systemically. This study will test the safety and immune response of a recombinant HIV-1gp160 by nasal and mucosal routes alone or formulated with DC-Chol in healthy volunteers.

Timeline

Start

2003-06

Primary completion

—

Completion

2005-04

Drugs

Indications